Last reviewed · How we verify
ALA-1000
At a glance
| Generic name | ALA-1000 |
|---|---|
| Also known as | Depot Buprenorphine Formulation |
| Sponsor | Alar Pharmaceuticals Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Single Ascending Dose Study of ALA-1000 (PHASE1)
- Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALA-1000 CI brief — competitive landscape report
- ALA-1000 updates RSS · CI watch RSS
- Alar Pharmaceuticals Inc. portfolio CI